1
Jun 2026
Lower Alzheimer’s amyloid levels in Black and Latinx adults
Findings show lower amyloid PET positivity in Black and Latinx adults with cognitive impairment, highlighting disparities in dementia diagnosis and treatment.
Stay Informed!
1
Jun 2026
Global policy gaps slow biosimilar adoption and access
Nine out of 10 prescriptions are filled by generic drugs - FDA-approved carbon copies of brand-name drugs with expired patents.
1
Jun 2026
Online resources on AI and cancer lack quality, need improvement
Online information about artificial intelligence (AI) and its impact on cancer research and treatment for both the patient and general-public audiences is limited, and the available webpages and videos are largely of low quality, difficult to read, and frequently omit risks of AI use, according to new research presented today at the at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9000) and led by researchers from the Abramson Cancer Center (ACC) of the University of Pennsylvania and Penn's Perelman School of Medicine.
1
Jun 2026
New PET imaging tracks tumor progression and cardiac inflammation during cancer therapy
A novel PET imaging approach enables simultaneous visualization of tumor progression and cardiac inflammatory responses during cancer treatment.
1
Jun 2026
PSMA PET detects high-risk prostate cancer bone metastases
Compared to conventional imaging techniques, prostate specific membrane antigen (PSMA) PET imaging provides superior detection of bone metastases in prostate cancer patients a critical indicator of a patient's long-term survival.
1
Jun 2026
New imaging method distinguishes inflammation from lung fibrosis
A new SPECT/CT imaging approach can accurately differentiate inflammation from fibrosis in interstitial lung disease (ILD) patients, according to new research presented at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting.
1
Jun 2026
Justicia carnea extract alleviates oxidative stress in pancreatitis
Chronic pancreatitis is an inflammatory disease and is difficult to manage despite advancements in medical science.
1
Jun 2026
Hypoxia-gated AAV enables targeted treatment for advanced NSCLC
Adeno‑associated virus (AAV) vectors offer safety and durable expression but lack tumor specificity. This hypothesis proposes an NSCLC‑directed, hypoxia‑responsive AAV platform that integrates MGS4 peptide‑guided capsid targeting with dual hypoxia‑responsive element (HRE)‑gated promoters driving Q‑CXCL9‑Fc (chemokine) and miR‑30‑based shRNA against mesothelin (MSLN).
1
Jun 2026
Mesenchymal drift may explain how aging cells lose their identity
Mesenchymal drift may help explain how cells lose stable identity and acquire pro-fibrotic, inflammatory mesenchymal traits during aging. The review proposes MD as a unifying framework that links multiple hallmarks of aging and highlights partial reprogramming as a potential, but still preclinical, way to counteract this process.
1
Jun 2026
New T-cell engager therapy shows effectiveness in advanced solid tumors
A team led by researchers from the National Center for Tumor Diseases (NCT/UCC) Dresden at the Carl Gustav Carus University Hospital (UKD) and the Carl Gustav Carus Faculty of Medicine at the TUD Dresden University of Technology will present clinical results for the first time on May 31, 2026, at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) regarding a new cancer immunotherapy for the treatment of advanced tumors.
